NCT04454437: Sacituzumab Govitecan in Chinese Patients With mTNBC of at Least 2 Prior Treatments

Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 2
Drug Category: Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have received at least 2 prior standard of care chemotherapy regimens
Exclusions: Patients NOT previously treated with a taxane; Patients with a history of or current central nervous system (CNS) metastases

Comments are closed.

Up ↑